19 drugs · 6 complete · 13 partly written · 0 not yet written
Drugs
The drug menu. What each drug is, what it does, how it works, and what went right or wrong. Failures are not hidden.
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
-
1999 adenoviral gene transfer trial for OTC deficiencyA 1999 safety trial of an adenoviral vector carrying the OTC gene, ended by the death of an 18-year-old participant from a systemic inflammatory response. Gene therapy OTC (ornithine transcarbamylase) gene product, supplied in liver cells Urea cycle Partial ornithine transcarbamylase (OTC) deficiency 1999 failed-in-trials failed complete
What happened. In a dose-escalation safety study of an adenoviral vector carrying the OTC gene, an 18-year-old participant with partial OTC deficiency died 98 hours after the top dose was infused into the liver artery. The cause was a systemic inflammatory response to the vector. The trial was stopped and gene therapy changed how it tests immune risk.
-
Axicabtagene ciloleucel (Yescarta)Axicabtagene ciloleucel is an autologous CD19-directed CAR T cell product approved for refractory large B-cell lymphoma. CAR T cell therapy CD19 CD3 zeta T-cell activation signalling CD28 costimulation Refractory large B-cell lymphoma in adults 2017 approved worked partly written
What it is in one breath. A CD19 CAR T product for adults with refractory large B-cell lymphoma. In the ZUMA-1 trial 82% of 101 treated patients responded and 54% had a complete response, with serious cytokine release and neurologic events in a minority.
-
Comirnaty (BNT162b2)Comirnaty is a nucleoside-modified mRNA vaccine in lipid nanoparticles that encodes the SARS-CoV-2 spike protein; in the pivotal trial it prevented 95 percent of symptomatic cases. mRNA medicines and vaccines SARS-CoV-2 spike glycoprotein (encoded antigen) Innate and adaptive immune response to the encoded spike Prevention of COVID-19 (active immunisation) 2020 approved worked partly written
The short version. Comirnaty is a lipid-nanoparticle mRNA vaccine that makes cells produce the SARS-CoV-2 spike protein so the immune system learns it. In a trial of 43,548 people, 8 cases occurred in the vaccine group and 162 in the placebo group, a reported efficacy of 95 percent.
-
CVnCoV (CureVac COVID-19 mRNA vaccine candidate)CVnCoV was a chemically unmodified mRNA vaccine candidate that showed 48.2 percent efficacy in its phase 2b/3 trial and was never authorised. mRNA medicines and vaccines SARS-CoV-2 spike glycoprotein (encoded antigen) Innate and adaptive immune response to the encoded spike Prevention of COVID-19 (active immunisation) 2021 failed-in-trials failed partly written
The short version. CVnCoV, an unmodified mRNA vaccine at 12 micrograms, was tested in 39,680 people across ten countries. It showed 48.2 percent efficacy against symptomatic disease (83 versus 145 cases). The company stopped its development and EMA ended its rolling review.
-
Fetal tissue transplants for Parkinson diseaseFetal tissue transplants put dopamine-rich midbrain tissue from fetuses into the brain of people with Parkinson disease; two sham-controlled trials missed their main goals and many grafted patients developed involuntary movements. Stem cell therapy Dopamine-producing neurons of the nigrostriatal pathway (replaced, not blocked); target region: the putamen Dopamine signalling from substantia nigra to striatum Severe Parkinson disease 2001 failed-in-trials failed partly written
What was tried. Developing dopamine-producing neurons from fetal brain tissue were implanted into the putamen of people with severe Parkinson disease. Open trials looked good, but two sham-controlled trials did not show a clear benefit, and many grafted patients developed involuntary movements even when off their medication.
-
HoloclarHoloclar is a patient's own limbal stem cells, grown on a fibrin carrier and placed on the burned eye to rebuild the surface of the cornea. Stem cell therapy Limbal stem cells of the corneal epithelium (a tissue to be rebuilt, not a molecular target) Renewal of the corneal epithelium by limbal stem cells Moderate to severe limbal stem-cell deficiency caused by physical or chemical eye burns, in adults 2015 approved worked partly written
What it is. A patient's own corneal stem cells, taken as a tiny biopsy from a healthy part of the eye, multiplied in a laboratory on a fibrin sheet, and put back on the burned eye by a surgeon. It is made for one patient only and cannot be given to anyone else.
-
JCAR015JCAR015 was a CD19 CAR T cell product for adult acute lymphoblastic leukemia whose development stopped in 2017 after deaths from brain swelling. CAR T cell therapy CD19 CD3 zeta T-cell activation signalling Relapsed or refractory B-cell acute lymphoblastic leukemia in adults 2017 discontinued failed partly written
What happened in one breath. A CD19 CAR T product for adult leukemia worked, then five patients died of brain swelling across two trial holds. Juno stopped the programme on 2 March 2017, citing patient factors, the chemotherapy and product factors, timing and better pipeline candidates.
-
Lantidra (donislecel)Lantidra is purified islet cells from deceased donors, infused into the portal vein of adults with type 1 diabetes and repeated severe hypoglycemia; it works only while immune-suppressing drugs are taken. Stem cell therapy Pancreatic beta cells (replaced) Glucose-regulated insulin secretion Adults with type 1 diabetes unable to approach target HbA1c because of repeated severe hypoglycemia despite intensive management 2023 approved mixed partly written
What it is. Donor islets: the insulin-making clusters from a deceased donor's pancreas, purified and dripped through a catheter into the liver's portal vein. The FDA approved it on 28 June 2023 for a narrow group of adults with type 1 diabetes. It works only while drugs hold the immune system back.
-
Luxturna (voretigene neparvovec)A one-time subretinal AAV2 gene therapy that supplies RPE65 to the retina in inherited retinal dystrophy. Gene therapy RPE65 (visual cycle enzyme), supplied by a new gene copy Visual cycle in retinal pigment epithelium RPE65-mediated inherited retinal dystrophy (biallelic RPE65 mutations) 2017 approved worked complete
What it is and what happened. Luxturna is an AAV2 gene therapy injected under the retina to give cells a working RPE65 gene. In its randomised phase 3 trial, 13 of 20 treated people passed the mobility test at the lowest light level against none of the controls, with no product-related serious adverse events. It is approved.
-
Nirmatrelvir (given with ritonavir)An oral SARS-CoV-2 main-protease inhibitor whose optimisation traded some enzyme potency for absorption. a record that is not published here SARS-CoV-2 main protease (3CL protease, Mpro) not yet written COVID-19 not yet written not yet written worked partly written
The lesson for lead optimisation. A cell-assay number belongs to the compound and the cell. The precursor looked far weaker in monkey cells than its enzyme potency suggested, in large part because the cells pump it out; the dose target was set from human-cell potency instead. Absorption, not enzyme potency, was what the oral series had to fix.
-
Nusinersen (Spinraza)Nusinersen is an antisense oligonucleotide injected into the spinal fluid that changes how the SMN2 gene is spliced so that children with spinal muscular atrophy make more full-length SMN protein. Antisense oligonucleotide (ASO) SMN2 pre-mRNA (a sequence in the intron downstream of exon 7) Pre-mRNA splicing of SMN2 SMN protein production Spinal muscular atrophy 2016 approved worked complete
In brief. Nusinersen is a short chemically armoured strand that sticks to one RNA in spinal muscular atrophy and changes how it is spliced, so a missing protein is made. It is injected into the spinal fluid and lasts for months. In infants it beat a sham procedure: 51 percent of treated infants met the motor-milestone endpoint against 0 percent of controls.
-
Patisiran (Onpattro)Patisiran is an siRNA against transthyretin mRNA, packed in a lipid nanoparticle and given by intravenous infusion, which slowed nerve damage in hereditary transthyretin amyloidosis. siRNA TTR (transthyretin) mRNA, mutant and wild-type RNA interference transthyretin amyloid formation retinol-binding protein and vitamin A transport Hereditary transthyretin-mediated amyloidosis with polyneuropathy (stage 1 or 2, adults, per the European authorisation) 2018 approved worked partly written
The short version. Patisiran switches off much of the liver's production of transthyretin by sending a matching RNA into liver cells. In the 225-patient APOLLO trial, nerve damage scores rose 28.0 points on placebo and fell 6.0 on the drug at 18 months. A fat particle gets the RNA in. Infusion reactions and low vitamin A are the costs.
-
Retroviral gene therapy for SCID-X1A gammaretroviral gene therapy that corrected X-linked severe combined immunodeficiency in most patients and caused T-cell leukaemia in several of them. Gene therapy IL2RG (interleukin-2 receptor gamma chain), supplied by a new gene copy Cytokine receptor signalling in T-cell development X-linked severe combined immunodeficiency (SCID-X1) 2003 investigational mixed complete
What happened. Nine of ten infants with SCID-X1 had their immune systems restored by retroviral gene transfer into their own marrow cells. Years later, four of the nine developed T-cell leukaemia because the vector had inserted next to a cancer-promoting gene and its enhancer switched it on. Most were cured of the leukaemia by chemotherapy.
-
RevusiranRevusiran was a sugar-tagged siRNA against transthyretin for amyloid heart disease; its phase 3 trial was stopped early after more patients died on the drug than on placebo, and the cause was not found. siRNA TTR (transthyretin) mRNA RNA interference transthyretin amyloid formation Hereditary transthyretin-mediated amyloidosis with cardiomyopathy 2016 failed-in-trials failed partly written
The short version. Revusiran targeted the same protein as patisiran, but for heart disease. ENDEAVOUR was stopped early: 18 of 140 treated patients died on treatment against 2 of 66 on placebo. Lowering of transthyretin was the same in those who died and those who lived. The investigators found no cause and say the drug cannot be excluded.
-
TGN1412 (anti-CD28 superagonist antibody)TGN1412 is an anti-CD28 antibody that in a 2006 first-in-human trial caused a life-threatening cytokine storm in all six healthy volunteers who received it, though animal safety testing had not predicted it. Therapeutic monoclonal antibodies CD28 T cell co-stimulation Cytokine release None stated in the sources opened; it was given to healthy volunteers in a first-in-human trial 2006 failed-in-trials failed partly written
The short version. TGN1412 was an antibody that switches T cells on by pressing CD28. In March 2006 six healthy volunteers received a single infusion. Within 90 minutes all six had a systemic inflammatory response, within 12 to 16 hours they were critically ill, and all survived. Animal safety testing had not predicted this.
-
Tisagenlecleucel (Kymriah)Tisagenlecleucel is an autologous CD19-directed CAR T cell product approved for B-cell leukemia and lymphomas. CAR T cell therapy CD19 CD3 zeta T-cell activation signalling 4-1BB (TNFRSF9) costimulation Relapsed or refractory B-cell acute lymphoblastic leukemia up to age 25 Large B-cell lymphoma Follicular lymphoma 2017 approved worked partly written
What it is in one breath. A living drug made from the patient's own T cells. A gene for a receptor aimed at CD19 is added outside the body, the cells are multiplied and given back by drip. In the decisive trial 81% of 75 young patients with relapsed leukemia went into remission within three months.
-
TominersenTominersen is an antisense oligonucleotide given into the spinal fluid to lower huntingtin, the protein behind Huntington disease; it lowered the protein but patients did not improve. Antisense oligonucleotide (ASO) HTT (huntingtin) RNA Huntingtin production Huntingtin RNA lowering Huntington disease 2021 failed-in-trials failed complete
In brief. Tominersen tried to lower huntingtin, the protein behind Huntington disease. It was injected into the spinal fluid. It did lower the protein, yet the people dosed every 2 months did worse than placebo and dosing was stopped. The reason is not established.
-
Trastuzumab (Herceptin)Trastuzumab is an antibody against the HER2 receptor that, added to chemotherapy, lengthened survival in women whose breast cancer over-makes HER2, at the cost of heart damage. Therapeutic monoclonal antibodies ERBB2 (HER2) HER2 / EGFR-family receptor signalling Antibody-dependent cellular cytotoxicity HER2-overexpressing breast cancer (metastatic and adjuvant) not yet written approved worked partly written
The short version. Trastuzumab is an antibody that sticks to HER2, a growth-signal receptor that 25 to 30 percent of breast cancers over-make. Added to chemotherapy in 469 women it lengthened median survival from 20.3 to 25.1 months. The cost was heart dysfunction, 27 percent versus 8 percent when given with an anthracycline.
-
Zolgensma (onasemnogene abeparvovec)A one-time intravenous gene therapy that delivers a working SMN gene inside an AAV9 shell to infants with spinal muscular atrophy. Gene therapy SMN1 gene product (survival motor neuron protein), supplied by a new gene copy Survival motor neuron protein production in motor neurons Spinal muscular atrophy (type 1 in the pivotal trials) 2019 approved worked complete
What it is and what happened. Zolgensma is a one-time infusion of a harmless-shell virus carrying a working copy of the SMN gene, for babies with spinal muscular atrophy. In the pivotal trial 19 of 21 infants were alive without permanent ventilation, against roughly one in four surviving past 14 months in natural history. It is approved, but the label warns of liver failure.